EXICURE, INC. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On November 19, 2026, Exicure entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd. to acquire an equity interest (20–100%, exact percentage and share exchange ratio to be determined) in NeuroQ and provide up to $500,000 in development funding. NeuroQ acquired the X-CUE augmented-reality smart-glasses technology (targeting Parkinson's freezing-of-gait) from Laonz and will lead clinical evaluation (anticipated ~6 months) and commercialization, with Exicure providing strategic support.
Why this rating
Strategic diversification into medical devices is material for a $16.4M company; $500K cash commitment is ~3% of market cap; acquisition structure remains unresolved, creating execution risk. Technology maturity (10+ years, ready for trials) supports credibility but commercialization highly uncertain.
Tradability signal
SHORT
conviction 19/100 · expected -0.32% over 4 hrs
SHORT (fade the pop): stock already ran +4.3% on this news, and positive calls in this cell have historically given the pop back (-0.33% over 4 hrs, n=592). Reversion play, lower conviction by design. Exit plan: HARD stop 5% against entry — default width (volatility unmeasured), fixed, not trailing (trails test terribly on these names) — time exit 4 hrs.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.92 ▼ 4.17% | at our read · unknown $0.96 | +10 min · unknown $0.93 ▼ 3.24% | +30 min · unknown $0.93 ▼ 3.24% | +1 hr · unknown $0.93 ▼ 3.29% | +4 hrs · unknown $0.90 ▼ 6.24% |
The stock had already moved +4.35% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.